AGE-SPECIFIC DIFFERENCES IN DURATION OF CLINICAL PROTECTION AFTER VACCINATION WITH MENINGOCOCCAL POLYSACCHARIDE A VACCINE

@article{Reingold1985AGESPECIFICDI,
  title={AGE-SPECIFIC DIFFERENCES IN DURATION OF CLINICAL PROTECTION AFTER VACCINATION WITH MENINGOCOCCAL POLYSACCHARIDE A VACCINE},
  author={Arthur L. Reingold and Allen W. Hightower and Gail Bolan and EllenE. Jones and H. Tiendrebeogo and Claire V. Broome and Gloria W. Ajello and Catherine Adamsbaum and Catherine J. Phillips and Adamou Yada},
  journal={The Lancet},
  year={1985},
  volume={326},
  pages={114-118}
}
Sequential case-control studies were used to monitor changes in the clinical protection induced by group A meningococcal polysaccharide vaccine over a 3-year period. Overall, vaccine efficacy declined from 87% 1 year after vaccination to 70% and 54% at 2 and 3 years, respectively. When stratified by age at time of vaccination the data showed that, although vaccine efficacy remained high in children greater than or equal to 4 years of age (vaccine efficacy 85%, 74%, and 67% at 1, 2, and 3 years… Expand
Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.
TLDR
Sustained protection of children against group A meningococcal disease will require the development of vaccines that are immunogenic in infants and that can induce T cell memory. Expand
An epidemiological and serological study on duration of protection after meningococcal Group A polysaccharide (APS) vaccination
TLDR
The immune response improved with age and pre-existing natural immunity, and the duration of protection, and a rational vaccination scheme which controlled a predicted epidemic was suggested. Expand
Duration of antibody response after meningococcal polysaccharide vaccination in US Air Force personnel.
TLDR
The long-term kinetics of the immunologic response after vaccination of adults with Neisseria meningitidis polysaccharide vaccine is unknown and the serologic measure of protection against meningococcal disease are important for evaluation of candidate vaccines and development of recommendations for immunization. Expand
Antibody Persistence and Response to a Booster Dose of a Quadrivalent Conjugate Vaccine for Meningococcal Disease in Adolescents
TLDR
A subsequent dose of MenACWY-CRM elicited an adequate antibody response, regardless of vaccine history, and provided a broad and persistent immune response in adolescents. Expand
Immunologic memory 5 years after meningococcal A/C conjugate vaccination in infancy.
TLDR
Antibody levels and immunologic memory were assessed in 5-year-old Gambian children who received meningococcal A/C conjugate vaccination (MenA/C) in infancy; however, MPS challenge at 2 years interfered with a subsequent memory response. Expand
A day care-based study of the efficacy of Haemophilus b polysaccharide vaccine.
TLDR
The efficacy of the currently used HBPV is less than expected from previous studies and the usefulness of case-control studies for monitoring vaccine efficacy following licensure is pointed out. Expand
Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease.
TLDR
The tetravalent polysaccharide Mencevax ACWY meningococcal vaccine was well tolerated and immunogenic in subjects aged 2-30 years in Taiwan. Expand
Immunogenicity and immunological priming of the serogroup a portion of a bivalent meningococcal A/C conjugate vaccine in 2-year-old children.
TLDR
Meningococcal serogroup A (MenA)-specific IgG geometric mean avidity indices (GMAIs) increased 1 month after vaccination with MACC and MACP, but a constant GMAI was maintained in the MACC-vaccinated cohort, despite declining MenA- specific IgG antibody levels. Expand
Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines.
  • G. Poland
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2010
TLDR
Efforts to prevent invasive meningococcal disease remain challenging, because there is neither an immunogenic vaccine for infants nor a vaccine to prevent serogroup B disease that is currently licensed. Expand
Group A Antibody Persistence Five Years After Meningococcal Polysaccharide Vaccination in the Sudan
TLDR
Recommendations for periodic meningococcal polysaccharide vaccination every 3 to 5 years to maintain group A immunity may be more appropriate for persons living outside of endemic areas than for persons residing in endemic regions since immunity in endemic areas can be maintained by periodic exposure to group A organisms, even during periods between epidemics. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 16 REFERENCES
Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.
TLDR
The results suggest that routine immunization of young infants with group A vaccine may result in long-lasting immunity and the usefulness of the presently available group C vaccine appears to be limited to the control of epidemics. Expand
Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
TLDR
Meningococcal Group A vaccine appears efficacious in young infants and children, although five to seven cases of meningitis or sepsis would have been expected within the year. Expand
Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.
TLDR
With increasing age, the decrease of the vaccination-induced antibody levels was progressively slower throughout the age bracket studied, while in infants aged 12-17 months, the decline of antibody level was more rapid, so that an elevated antibody titer was not maintained for more than one year. Expand
EFFECT OF GROUP-A MENINGOCOCCAL VACCINE IN ARMY RECRUITS IN FINLAND
TLDR
The total number of cases of group-A meningococcal disease was reduced to non-epidemic levels at a time when 36% of the men in service were vaccinated, and has remained low for the next twelve months even though the epidemic in the general population continued. Expand
The duration of the antibody response to meningococcal vaccination in an African village.
TLDR
When pooled serum samples from the same subjects were tested for meningococcal antibodies by radioimmunoassay, immunized subjects were found to have significantly higher mean levels of both group A and group C meningitiscal antibodies than the controls. Expand
A second controlled field trial of a serogroup A meningococcal polysaccharide vaccine in Alexandria.
TLDR
The vaccine was found to reduce to less than half the rate of new acquisition of serogroup A meningococci during the period immediately following immunization, and the duration of the carrier state was shortened in the immunized group. Expand
A controlled field trial of a serogroup A meningococcal polysaccharide vaccine.
TLDR
A controlled field trial of a serogroup A meningococcal polysaccharide vaccine was conducted at three locations in Egypt during the winter cerebrospinal meningitis (CSM) season of 1971-72 and a significant serological response was elicited in the majority of the vaccinated students. Expand
Antibody Responses to Meningococcal Polysaccharide Vaccines
TLDR
Results have shown that the radioactive antigen binding assay is preferable to the IHA test as a measure of antibody response, and Optimal antibody response to the group A vaccines appears to be directly related to the molecular size of the preparation. Expand
The immune response to a meningococcal polysaccharide vaccine in an African village.
TLDR
The antibody response to group C meningococcal polysaccharide vaccine was studied in a Nigerian village and was not influenced by mild degrees of malnutrition but children with clinical marasmus or kwashiorkor were excluded from the study. Expand
Immunogenicity of the group A and group C meningococcal polysaccharides in children.
TLDR
Elevated levels of specific antibody were found in the sera of children 10-15 months after immunization with the group A or the group C antigen. Expand
...
1
2
...